Glauconix Biosciences announces 2020 attending conferences
ALBANY, NY January 27, 2020– Glauconix Biosciences, Inc., a specialty pharmaceutical company that helps expedite R&D of pharmaceuticals using its platform technology to develop ex vivo-like 3D Human Tissue Models for accelerating therapeutic innovation and drug discovery, announced today the conferences/summits they have selected to participate/attend in the 2020 calendar year. The conference/ summits are:
GLAUCOMA 360, SAN FRANCISCO - FEBRUARY 6-8
ARVO ANNUAL MEETING 2020, BALTIMORE, MD - MAY 3-7
ASGCT ANNUAL MEETING, BOSTON, MA - MAY 12-15
OIS-ANTERIOR SEGMENT, CAMBRIDGE, MA - MAY 14
BIO INTERNATIONAL CONVENTION 2020, SAN DIEGO, CA - JUNE 8-11
OIS- RETINA 2020, SEATTLE, WA -JULY 23
ISER 2020, BUENOS AIRES, ARGENTINA - OCTOBER 25-29
AAO 2020, LAS VEGAS, NV - NOVEMBER 14-17
About Glauconix Biosciences
Glauconix Biosciences is a leading developer of ophthalmic ex-vivo dynamic 3D human tissue models for accelerating therapeutic innovation and drug discovery. Their 3D tissue models can de-risk ophthalmic assets and expedite drug development. Glauconix adds value to their clients and partners by expediting early identification and validation of effective compounds or biologics in the preclinical phase and those entering clinical trials.